Top stories

Maharashtra FDA cancels Cipla's Pune warehouse licences; company says it is reviewing order

• Maharashtra FDA cancelled Cipla's Pune warehouse licences over alleged violations
• Cipla said it is reviewing the order and maintains the facility follows protocols
• The licence action creates regulatory and distribution risk for Cipla's India pharma business

Granules India incorporates wholly owned subsidiary in Brazil

• Granules India incorporated Triton Farmaceutica Do Brasil Ltda as a wholly owned subsidiary in Brazil
• The subsidiary will manufacture, promote, sell and distribute pharmaceuticals and related products in Brazil
• Brazil expansion gives Granules India a new market for its pharmaceutical business

Global Health expands Delhi-NCR footprint with upcoming Medanta hospital in Ghaziabad- details inside

• Global Health acquired land in Ghaziabad for a planned Medanta hospital
• Expansion may benefit Indian hospital operators competing in Delhi-NCR

New launches, chronic portfolio to maintain growth for Zydus Lifesciences

• Domestic formulations, chronic therapies and US launches have supported Zydus Lifesciences’ growth and rally
• Valuations now stand above…
• Growth supports Zydus Lifesciences, though elevated valuations may limit further gains

FDA cancels wholesale drug sales license of Cipla Pharma & Life sciences Ltd

Pharma, textiles, EVs seek GST fix for duty inversions

Hospital stocks: can strong demand offset regulatory risks?

• Supreme Court scrutiny of medicine mark-ups has raised concerns over hospital margins
• Robust demand for tertiary care continues to support hospitals
• Margin risks and care demand affect Indian hospital operators

Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

• Western biopharma companies are increasingly turning to China to source drug innovation
• The shift comes as pharma's patent cliff draws closer

Drug panel rejects cap on wholesale licences

Jefferies is bullish on 6 healthcare stocks with upside potential of up to 46%. Own any?

• Hospital stocks extended losses amid scrutiny over cancer-drug markups and pharmacy practices
• Jefferies maintained Buy ratings on six healthcare stocks, with potential upside of up to 46%
• Regulatory scrutiny pressures hospital stocks, while Jefferies’ calls may support Indian healthcare sentiment

SEBI clears Carlsberg India, TMC Transformers, Ujin Pharma and Matangi Rubber IPOs

• SEBI approved IPOs for Carlsberg India, TMC Transformers, Ujin Pharma and Matangi Rubber
• The approvals clear the four companies to move ahead with their public offerings
• The approvals add potential new listings for Indian IPO investors

Nurses at Boston’s Brigham and Women’s Hospital Plan to Strike